Analysis for HSY
- 📈 Growth — 12/30
- 💰 Profitability — 16/20
- 🏦 Financial Health — 15/20
- 💵 Valuation — 12/20
- ⚠️ Risk — 6/10
Summary:
📈 Growth & Financial Trajectory
Eight quarters show revenue hovering around the mid‑$3B range, from $3.252B in 2024Q1 to $3.091B in 2025Q4, a modest decline. Net income declined from $797.5M to $320.0M, with a mid‑year trough at $62.7M in 2025Q2 before rebounding to $320.0M in 2025Q4. Gross margin swung from the mid‑40s/50% range in 2024 to the high‑30s in 2025, signaling shifting mix or costs. Cash from operations remained positive through most quarters, while investing cash outflows intensified late in the period, tempering overall free cash flow.
💰 Margins & Cash Flow
Gross margin ranged roughly from the low 30s to the mid‑50s (peaking at ~54% in 2024Q4), with 2025 quarters largely in the mid‑30s. Operating leverage supported consistent positive operating income, e.g., $434M and $444.9M in 2025Q2–Q4. Net cash flow from operating activities stayed robust (e.g., $841.9M in 2025Q3 and $926.6M in 2025Q4); investing cash flow was negative in several quarters (e.g., $(896.5M) in 2025Q4), weighing free cash flow; financing was mixed.
🛡️ Balance Sheet & Liquidity
Total assets around $13.74B; liabilities about $9.10B and equity near $4.64B at 2025Q4. Current assets of about $3.60B vs current liabilities of $3.01B yield a healthy, but modest, liquidity cushion (current ratio ~1.19). Long‑term debt hovered near $5.18B–$5.78B, with coverage supported by steady operating cash flow.
⚠️ Key Drivers & Risks
- Drivers: resilient consumer staple demand; strong brand portfolio
- Risks: quarterly earnings volatility; sensitivity to input costs and macro shifts; valuation sensitivity